http://data.rnaiscience.com/ 2026-06-22T04:09:52-04:00 daily 1.0 http://data.rnaiscience.com/congresses/international-congress-inborn-errors-metabolism-2025 2026-06-24T01:42:12-04:00 0.5 http://data.rnaiscience.com/congresses/european-society-cardiology-2025 2026-06-24T01:42:31-04:00 0.5 http://data.rnaiscience.com/congresses/canadian-association-for-population-therapeutics-2025 2026-06-24T02:20:51-04:00 0.5 http://data.rnaiscience.com/congresses/european-attr-amyloidosis-meeting-2025 2026-06-24T02:22:09-04:00 0.5 http://data.rnaiscience.com/congresses/heart-failure-society-america-2025 2026-06-24T02:22:43-04:00 0.5 http://data.rnaiscience.com/congresses/european-society-cardiology-2025-cv 2026-06-24T01:42:41-04:00 0.5 http://data.rnaiscience.com/congresses/alzheimers-association-international-conference-2025 2026-06-24T01:01:41-04:00 0.5 http://data.rnaiscience.com/congresses/ph1-european-renal-association-2025 2026-06-24T01:01:00-04:00 0.5 http://data.rnaiscience.com/congresses/european-society-paediatric-urology-2025 2026-06-24T02:00:33-04:00 0.5 http://data.rnaiscience.com/congresses/ph1-international-pediatric-transplant-association-2025 2026-06-24T02:20:02-04:00 0.5 http://data.rnaiscience.com/congresses/international-porphyrias-symposium-2025 2026-06-24T02:24:35-04:00 0.5 http://data.rnaiscience.com/congresses/ispor-eu-2025 2026-06-24T02:32:14-04:00 0.5 http://data.rnaiscience.com/congresses/american-heart-association-2025 2026-06-24T02:29:50-04:00 0.5 http://data.rnaiscience.com/congresses/american-association-study-liver-diseases-2025 2026-06-24T02:31:01-04:00 0.5 http://data.rnaiscience.com/congresses/american-heart-association-2025-cv 2026-06-24T02:28:22-04:00 0.5 http://data.rnaiscience.com/congresses/global-cardiovascular-clinical-trialists-forum-2025 2026-06-24T02:34:28-04:00 0.5 http://data.rnaiscience.com/congresses/clinical-trials-alzheimers-disease-2025 2026-06-24T02:32:37-04:00 0.5 http://data.rnaiscience.com/congresses/european-society-paediatric-nephrology-2025 2026-06-24T02:25:24-04:00 0.5 http://data.rnaiscience.com/congresses/american-society-nephrology-2025 2026-06-24T02:25:57-04:00 0.5 http://data.rnaiscience.com/congresses/international-stroke-conference-2026 2026-06-24T02:35:36-04:00 0.5 http://data.rnaiscience.com/congresses/american-college-cardiology-2026-attr 2026-06-24T02:47:13-04:00 0.5 http://data.rnaiscience.com/congresses/american-college-cardiology-2026-cv 2026-06-24T02:48:02-04:00 0.5 http://data.rnaiscience.com/congresses/thrombosis-and-hemostasis-summit-of-north-america-2026 2026-06-24T02:36:10-04:00 0.5 http://data.rnaiscience.com/congresses/american-academy-neurology-2026 2026-06-24T02:53:11-04:00 0.5 http://data.rnaiscience.com/congresses/belgian-society-nephrology-2026 2026-06-24T02:53:54-04:00 0.5 http://data.rnaiscience.com/congresses/pediatric-academic-societies-2026 2026-06-24T02:54:32-04:00 0.5 http://data.rnaiscience.com/congresses/digestive-disease-week-2026 2026-06-24T02:55:00-04:00 0.5 http://data.rnaiscience.com/congresses/heart-failure-association-2026 2026-06-24T02:56:34-04:00 0.5 http://data.rnaiscience.com/congresses/european-society-hypertension-2026 2026-06-24T02:57:06-04:00 0.5 http://data.rnaiscience.com/congresses/european-renal-association-2026-cv 2026-06-24T02:57:37-04:00 0.5 http://data.rnaiscience.com/congresses/european-renal-association-2026 2026-06-24T02:58:04-04:00 0.5 http://data.rnaiscience.com/congresses/peripheral-nerve-society-2026 2026-06-24T02:58:42-04:00 0.5 http://data.rnaiscience.com/congresses/american-transplant-2026 2026-06-20T00:00:14-04:00 0.5 http://data.rnaiscience.com/congresses/rna-therapeutics-symposium-2026 2026-06-24T10:43:43-04:00 0.5 http://data.rnaiscience.com/alnylam-rnai 2026-06-23T03:17:46-04:00 0.5 http://data.rnaiscience.com/connect-with-us 2026-06-22T03:45:10-04:00 0.5 http://data.rnaiscience.com/congresses 2026-06-22T03:43:40-04:00 0.5 http://data.rnaiscience.com/publications 2026-06-22T03:44:37-04:00 0.5 http://data.rnaiscience.com/publications/patient-experience-acute-hepatic-porphyria-and-after-long-term-givosiran-treatment 2026-03-20T05:40:35-04:00 0.5 http://data.rnaiscience.com/publications/effectiveness-and-utility-genetic-testing-establishing-diagnosis-hereditary 2026-03-20T08:45:23-04:00 0.5 http://data.rnaiscience.com/publications/impact-patisiran-polyneuropathy-hereditary-transthyretin-amyloidosis-patients-v122i-or 2026-03-20T05:59:06-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-transthyretin-amyloidosis-pooled-safety-analysis-helios-and-helios-b 2026-02-13T11:35:32-05:00 0.5 http://data.rnaiscience.com/publications/effects-vutrisiran-cardiac-structure-and-function-patients-transthyretin-amyloidosis 2026-03-20T08:24:56-04:00 0.5 http://data.rnaiscience.com/publications/effects-vutrisiran-cardiac-function-and-outcomes-patients-transthyretin-amyloidosis 2026-03-20T08:26:45-04:00 0.5 http://data.rnaiscience.com/publications/impact-vutrisiran-cardiac-biomarkers-patients-transthyretin-amyloidosis-cardiomyopathy 2026-02-13T12:03:30-05:00 0.5 http://data.rnaiscience.com/publications/realizing-therapeutic-potential-rapid-knockdown-transthyretin-rna-interference 2026-03-20T08:23:32-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-improves-survival-and-reduces-cardiovascular-events-attr-amyloid 2026-03-20T06:06:25-04:00 0.5 http://data.rnaiscience.com/publications/treatment-vutrisiran-people-transthyretin-amyloidosis-cardiomyopathy-plain-language 2026-03-20T06:08:57-04:00 0.5 http://data.rnaiscience.com/publications/impact-heart-failure-severity-vutrisiran-efficacy-transthyretin-amyloidosis 2026-03-20T05:47:47-04:00 0.5 http://data.rnaiscience.com/publications/impact-vutrisiran-functional-capacity-and-quality-life-transthyretin-amyloidosis 2026-03-20T08:40:02-04:00 0.5 http://data.rnaiscience.com/publications/diagnosis-hereditary-transthyretin-amyloidosis-patients-suspected-chronic-inflammatory 2026-03-20T08:20:28-04:00 0.5 http://data.rnaiscience.com/publications/worsening-heart-failure-outpatients-transthyretin-amyloidosis-and-cardiomyopathy 2026-03-20T06:49:52-04:00 0.5 http://data.rnaiscience.com/publications/journey-diagnosis-wild-type-transthyretin-mediated-attrwt-amyloidosis-path-multisystem 2026-03-18T09:43:02-04:00 0.5 http://data.rnaiscience.com/publications/add-treatment-zilebesiran-inadequately-controlled-hypertension-kardia-2-randomized 2026-03-20T05:55:56-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-lumasiran-advanced-primary-hyperoxaluria-type-1-24-month-follow 2026-03-20T05:44:38-04:00 0.5 http://data.rnaiscience.com/publications/outpatient-worsening-heart-failure-patients-transthyretin-amyloidosis-cardiomyopathy 2026-03-18T03:32:10-04:00 0.5 http://data.rnaiscience.com/publications/five-year-results-patisiran-hereditary-transthyretin-amyloidosis-polyneuropathy 2026-03-20T06:03:50-04:00 0.5 http://data.rnaiscience.com/publications/long-term-follow-givosiran-treatment-patients-acute-intermittent-porphyria-phase-12-48 2026-03-18T03:39:31-04:00 0.5 http://data.rnaiscience.com/publications/high-disease-burden-and-healthcare-resource-usage-patients-acute-porphyria-population 2026-03-18T04:11:12-04:00 0.5 http://data.rnaiscience.com/publications/randomized-placebo-controlled-study-givosiran-patients-acute-hepatic-porphyrias 2026-03-18T04:35:42-04:00 0.5 http://data.rnaiscience.com/publications/elevated-homocysteine-negatively-correlated-plasma-cystathionine-b-synthase-activity 2026-03-20T02:05:03-04:00 0.5 http://data.rnaiscience.com/publications/clinical-features-acute-attacks-chronic-symptoms-and-long-term-complications-among 2026-03-25T03:33:47-04:00 0.5 http://data.rnaiscience.com/publications/quantifying-impact-acute-hepatic-porphyria-well-being-patient-reported-outcomes 2026-03-20T08:46:31-04:00 0.5 http://data.rnaiscience.com/publications/effectiveness-patisiran-after-switching-tafamidis-treatment-hereditary-transthyretin 2026-03-18T04:32:18-04:00 0.5 http://data.rnaiscience.com/publications/neurofilament-light-chain-biomarker-hereditary-attr-amyloidosis 2026-03-18T12:01:58-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-patients-transthyretin-amyloidosis-cardiomyopathy 2026-03-18T04:25:07-04:00 0.5 http://data.rnaiscience.com/publications/impact-vutrisiran-exploratory-cardiac-parameters-hereditary-transthyretin-mediated 2026-03-18T06:28:50-04:00 0.5 http://data.rnaiscience.com/publications/patisiran-rnai-therapeutic-hereditary-transthyretin-mediated-amyloidosis-sub-analysis 2026-03-20T01:59:54-04:00 0.5 http://data.rnaiscience.com/publications/impact-baseline-neuropathy-severity-vutrisiran-treatment-response-phase-3-helios-study 2026-03-20T01:58:13-04:00 0.5 http://data.rnaiscience.com/publications/six-minute-walk-test-clinical-end-point-cardiomyopathy-clinical-trials-including-attr 2026-03-18T05:50:44-04:00 0.5 http://data.rnaiscience.com/publications/discovery-prevalence-transthyretin-ttr-mutations-us-centric-patient-population 2026-03-18T08:17:26-04:00 0.5 http://data.rnaiscience.com/publications/presence-v122i-variant-hereditary-transthyretin-mediated-amyloidosis-among-self 2026-03-20T08:33:39-04:00 0.5 http://data.rnaiscience.com/publications/gene-silencing-therapeutics-cardiology-review-article 2026-03-20T08:44:30-04:00 0.5 http://data.rnaiscience.com/publications/transthyretin-stabilising-mutation-t119m-not-associated-protection-against-vascular 2026-03-18T08:12:35-04:00 0.5 http://data.rnaiscience.com/publications/patisiran-rnai-therapeutic-hereditary-transthyretin-amyloidosis 2026-03-18T09:28:20-04:00 0.5 http://data.rnaiscience.com/publications/patisiran-treatment-patients-transthyretin-cardiac-amyloidosis 2026-03-18T06:50:31-04:00 0.5 http://data.rnaiscience.com/publications/effects-patisiran-rna-interference-therapeutic-cardiac-parameters-patients-hereditary 2026-03-18T09:08:46-04:00 0.5 http://data.rnaiscience.com/publications/association-patisiran-rna-interference-therapeutic-regional-left-ventricular 2026-03-18T09:55:16-04:00 0.5 http://data.rnaiscience.com/publications/effect-patisiran-stroke-volume-hereditary-transthyretin-mediated-amyloidosis-insights 2026-03-18T13:40:59-04:00 0.5 http://data.rnaiscience.com/publications/long-term-safety-and-efficacy-patisiran-hereditary-transthyretin-mediated-amyloidosis 2026-03-18T08:06:38-04:00 0.5 http://data.rnaiscience.com/publications/patisiran-pharmacokinetics-pharmacodynamics-and-exposure-response-analyses-phase-3 2026-03-18T09:29:40-04:00 0.5 http://data.rnaiscience.com/publications/patisiran-treatment-patients-hereditary-transthyretin-mediated-amyloidosis 2026-03-20T06:50:49-04:00 0.5 http://data.rnaiscience.com/publications/pharmacokinetics-and-pharmacodynamics-patisiran-patients-hattr-amyloidosis-and 2026-03-20T08:47:17-04:00 0.5 http://data.rnaiscience.com/publications/treatment-response-and-neurofilament-light-chain-levels-long-term-patisiran-hereditary 2026-03-18T06:59:46-04:00 0.5 http://data.rnaiscience.com/publications/impact-baseline-polyneuropathy-severity-patisiran-treatment-outcomes-apollo-trial 2026-03-18T07:23:52-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-vutrisiran-patients-hereditary-transthyretin-mediated-amyloidosis 2026-03-18T11:08:20-04:00 0.5 http://data.rnaiscience.com/publications/indirect-treatment-comparison-itc-efficacy-vutrisiran-and-tafamidis-hereditary 2026-03-18T07:08:32-04:00 0.5 http://data.rnaiscience.com/publications/zilebesiran-rna-interference-therapeutic-agent-hypertension 2026-03-18T12:05:19-04:00 0.5 http://data.rnaiscience.com/publications/strong-and-sustained-antihypertensive-effect-small-interfering-rna-targeting-liver 2026-03-18T08:42:44-04:00 0.5 http://data.rnaiscience.com/publications/rna-interference-therapeutics-targeting-angiotensinogen-ameliorate-preeclamptic 2026-03-20T07:23:40-04:00 0.5 http://data.rnaiscience.com/publications/final-results-illuminate-phase-3-clinical-trial-lumasiran-primary-hyperoxaluria-1 2026-02-13T11:10:33-05:00 0.5 http://data.rnaiscience.com/publications/investigating-pharmacodynamic-durability-galnac-sirna-conjugates 2026-03-25T03:07:37-04:00 0.5 http://data.rnaiscience.com/publications/no-evidence-brain-renin-angiotensin-system-activation-during-doca-salt-hypertension 2026-04-02T06:31:20-04:00 0.5 http://data.rnaiscience.com/publications/renoprotective-effects-small-interfering-rna-targeting-liver-angiotensinogen 2026-03-20T07:06:38-04:00 0.5 http://data.rnaiscience.com/publications/impact-vutrisiran-quality-life-and-physical-function-patients-hereditary-transthyretin 2026-03-18T07:02:48-04:00 0.5 http://data.rnaiscience.com/publications/distinguishing-characteristics-pediatric-patients-primary-hyperoxaluria-type-1-pedsnet 2026-03-20T08:50:34-04:00 0.5 http://data.rnaiscience.com/publications/rna-interference-zilebesiran-mild-moderate-hypertension-kardia-1-randomized-clinical 2026-03-20T01:52:07-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-lumasiran-patients-primary-hyperoxaluria-type-1-results-phase-iii 2026-03-18T12:07:27-04:00 0.5 http://data.rnaiscience.com/publications/randomized-clinical-trial-long-term-efficacy-and-safety-lumasiran-patients-primary 2026-03-18T09:49:17-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-givosiran-acute-hepatic-porphyria-final-results-randomized-phase 2026-03-20T01:21:27-04:00 0.5 http://data.rnaiscience.com/publications/phase-12-study-lumasiran-treatment-primary-hyperoxaluria-type-1-placebo-controlled 2026-03-18T08:31:43-04:00 0.5 http://data.rnaiscience.com/publications/disease-burden-patients-acute-hepatic-porphyria-experience-phase-3-envision-study 2026-03-20T01:00:53-04:00 0.5 http://data.rnaiscience.com/publications/patient-perspective-acute-hepatic-porphyria-sporadic-attacks-chronic-disease 2026-03-18T08:06:19-04:00 0.5 http://data.rnaiscience.com/publications/drug-drug-interaction-study-evaluating-effect-givosiran-small-interfering-ribonucleic 2026-03-18T08:12:30-04:00 0.5 http://data.rnaiscience.com/publications/primary-hyperoxaluria-type-1-disease-manifestations-and-healthcare-utilization-multi 2026-03-18T08:33:04-04:00 0.5 http://data.rnaiscience.com/publications/normal-reference-ranges-urinary-d-aminolevulinic-acid-and-porphobilinogen-levels 2026-03-18T08:05:46-04:00 0.5 http://data.rnaiscience.com/publications/characterising-healthy-adult-rare-hao1-knockout-support-therapeutic-strategy-primary 2026-03-20T04:00:55-04:00 0.5 http://data.rnaiscience.com/publications/detecting-rare-diseases-electronic-health-records-using-machine-learning-and-knowledge 2026-03-18T08:42:12-04:00 0.5 http://data.rnaiscience.com/publications/reducing-diagnostic-delays-acute-hepatic-porphyria-using-health-records-data-and 2026-03-18T08:34:33-04:00 0.5 http://data.rnaiscience.com/publications/lumasiran-rnai-therapeutic-primary-hyperoxaluria-type-1 2026-03-20T01:09:36-04:00 0.5 http://data.rnaiscience.com/publications/phase-3-trial-rnai-therapeutic-givosiran-acute-intermittent-porphyria 2026-03-20T03:41:47-04:00 0.5 http://data.rnaiscience.com/publications/pharmacokinetics-and-pharmacodynamics-small-interfering-ribonucleic-acid-givosiran 2026-03-20T01:07:28-04:00 0.5 http://data.rnaiscience.com/publications/population-pharmacokinetic-analysis-rnai-therapeutic-givosiran-patients-acute-hepatic 2026-03-18T08:35:11-04:00 0.5 http://data.rnaiscience.com/publications/explore-prospective-multinational-natural-history-study-patients-acute-hepatic 2026-03-18T09:47:44-04:00 0.5 http://data.rnaiscience.com/publications/pharmacokinetic-pharmacodynamic-model-urinary-d-aminolevulinic-acid-reduction-after 2026-03-18T08:35:52-04:00 0.5 http://data.rnaiscience.com/publications/phase-1-trial-rna-interference-therapy-acute-intermittent-porphyria 2026-03-20T03:47:47-04:00 0.5 http://data.rnaiscience.com/publications/explore-b-prospective-long-term-natural-history-study-patients-acute-hepatic-porphyria 2026-03-20T02:33:17-04:00 0.5 http://data.rnaiscience.com/publications/patient-perspective-acute-intermittent-porphyria-frequent-attacks-disease-intermittent 2026-03-20T01:21:47-04:00 0.5 http://data.rnaiscience.com/publications/hyperhomocysteinemia-acute-hepatic-porphyria-ahp-and-implications-treatment-givosiran 2026-03-20T02:38:29-04:00 0.5 http://data.rnaiscience.com/publications/quantification-oxalate-novel-lc-msms-assay-development-validation-and-application 2026-03-18T08:27:04-04:00 0.5 http://data.rnaiscience.com/publications/estimating-health-state-utilities-primary-hyperoxaluria-type-1-valuation-study 2026-03-18T08:33:31-04:00 0.5 http://data.rnaiscience.com/publications/qualitative-assessment-patient-experience-primary-hyperoxaluria-type-1-observational 2026-03-18T08:37:52-04:00 0.5 http://data.rnaiscience.com/publications/lumasiran-advanced-primary-hyperoxaluria-type-1-phase-3-illuminate-c-trial 2026-03-18T09:05:56-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-lumasiran-infants-and-young-children-primary-hyperoxaluria-type-1 2026-03-20T01:57:00-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-lumasiran-infants-and-young-children-primary-hyperoxaluria-type-0 2026-03-18T09:25:17-04:00 0.5 http://data.rnaiscience.com/publications/phase-3-trial-lumasiran-primary-hyperoxaluria-type-1-new-rnai-therapeutic-infants-and 2026-03-20T01:20:56-04:00 0.5 http://data.rnaiscience.com/publications/effect-vutrisiran-components-health-status-transthyretin-amyloidosis-cardiomyopathy 2026-04-06T13:12:00-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-vutrisiran-patients-hereditary-transthyretin-mediated 2026-04-06T13:11:54-04:00 0.5 http://data.rnaiscience.com/publications/efficacy-and-safety-vutrisiran-transthyretin-amyloid-cardiomyopathy-across-age 2026-04-06T13:12:28-04:00 0.5 http://data.rnaiscience.com/publications/benefits-patisiran-functional-capacity-attr-cardiac-amyloidosis-post-hoc-analysis 2026-04-06T13:11:18-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-patients-transthyretin-amyloidosis-cardiomyopathy-and-renal-impairment 2026-06-23T03:10:22-04:00 0.5 http://data.rnaiscience.com/publications/best-practices-and-key-barriers-amyloidosis-patient-care-us-specialized-amyloidosis 2026-06-04T01:05:29-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-east-asian-patients-transthyretin-amyloidosis-cardiomyopathy-post-hoc 2026-06-04T01:05:38-04:00 0.5 http://data.rnaiscience.com/publications/vutrisiran-mediated-knockdown-transthyretin-patients-attr-amyloidosis 2026-06-04T01:07:47-04:00 0.5 http://data.rnaiscience.com/acute-hepatic-porphyria-ahp 2026-06-22T03:46:01-04:00 0.5 http://data.rnaiscience.com/cardiovascular-cv 2026-06-22T03:49:01-04:00 0.5 http://data.rnaiscience.com/neurologic 2026-06-22T03:47:07-04:00 0.5 http://data.rnaiscience.com/primary-hyperoxaluria-type-1-ph1 2026-06-22T03:46:51-04:00 0.5 http://data.rnaiscience.com/transthyretin-amyloidosis 2026-06-22T03:46:36-04:00 0.5